Post Early Success, Bristol-Myers Ends Tests for Kidney Cancer

Post Early Success, Bristol-Myers Ends Tests for Kidney Cancer

Bristol-Myers Squibb Co, widely known BMS- a renowned pharmaceutical company in the United States declared on September 6, 2017, that they have succeeded in testing the combination therapy and treatment to boost overall survival in patients suffering from kidney cancer. This success has helped the company to end its trial before the planned schedule, despite previous reports generated had mixed results considering other chief goals.

The company mentioned in a statement that an amalgamation of Yervoy and Opdivo, its two key medications, showed higher total survival rates compared to a standard care medication that was used to treat formerly untreated patients suffering from metastatic or advanced renal cell carcinoma. In August 2017, Bristol- Myers quoted that the amalgamated treatment failed in improving progression-free cancer survival in most of the patients. However, it was successful in decreasing the size of the cancer tumor in many patients.

Research analyst from Leerink, Seamus Fernandez had written in a client note that, “we are of a belief that the total survival advantage is most likely to confirm the durability of the indication noticed on progression-free survival, thus resulting in an extremely high likelihood of medication approval.” As per the information given by Cowen and Co, the trials to gauge the complete survival rates are expected to be executed during the second half of 2019. Bristol-Myers added that the trail was ended before time after the results of a planned interim analysis were successful. This also helped the company shares to went up by 4.2 percent and reach a 52-week high amounting to US$ 62.415 this time.
The shares of Exelixis Inc- a rival pharmaceutical company which is in process of manufacturing a competitive treatment for kidney cancer, dropped down by 10 percent. In addition, trial results of Bristol-Myers increased hopes and expectations for lung cancer therapy from AstraZeneca Plc that failed to deliver progression-free survival in July.

You may be interested

Smart Nanotechnology Enlivens Wooden Ships and Artifacts
Business
Business

Smart Nanotechnology Enlivens Wooden Ships and Artifacts

Mohit Joshi - January 28, 2019

Scientists developed an innovative approach using ‘smart’ nanocomposites to conserve 16th-century British warship, the Mary Rose, and its artifacts. Shipwrecks are preserved in sediments under cold water,…

Researchers Discovered New Properties of Ferroelectric Crystal
Business
Business

Researchers Discovered New Properties of Ferroelectric Crystal

Mohit Joshi - January 25, 2019

Researchers discovered new properties of ferroelectric crystal, according to a study published on July 10, 2018. This study was conducted by a team of researchers from China.…

Researchers Develop Novel Antibody to Knockdown of Protein in Vertebrates
Healthcare
Healthcare

Researchers Develop Novel Antibody to Knockdown of Protein in Vertebrates

Mohit Joshi - January 24, 2019

Researchers from Technische Universität Dresden developed a synthetic antibody that improves functional analysis of proteins. A research led by Dr. Jörg Mansfeld of the Biotechnology Center of…

Most from this category